| mRNA |
Erlotinib |
CCLE |
pan-cancer |
AAC |
-0.35 |
3e-06 |
| mRNA |
lapatinib |
CCLE |
pan-cancer |
AAC |
-0.34 |
6e-06 |
| mRNA |
Vandetanib |
CCLE |
pan-cancer |
AAC |
-0.33 |
3e-05 |
| mRNA |
salermide:PLX-4032 (12:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.22 |
9e-05 |
| mRNA |
PLX4720 |
CTRPv2 |
pan-cancer |
AAC |
0.19 |
0.0002 |
| mRNA |
tivantinib |
CTRPv2 |
pan-cancer |
AAC |
-0.23 |
0.0002 |
| mRNA |
KX2-391 |
CTRPv2 |
pan-cancer |
AAC |
-0.17 |
0.0002 |
| mRNA |
dabrafenib |
CTRPv2 |
pan-cancer |
AAC |
0.24 |
0.0003 |
| mRNA |
BRD-K27188169:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.29 |
0.0004 |
| mRNA |
paclitaxel |
CTRPv2 |
pan-cancer |
AAC |
-0.16 |
0.0005 |